Pages that link to "Q37398320"
Jump to navigation
Jump to search
The following pages link to Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis (Q37398320):
Displaying 50 items.
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond (Q26766718) (← links)
- Myeloid-derived suppressor cells as therapeutic target in hematological malignancies (Q27010234) (← links)
- Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms (Q27692033) (← links)
- Coordinated regulation of myeloid cells by tumours (Q28395157) (← links)
- TPL2 kinase regulates the inflammatory milieu of the myeloma niche (Q33714724) (← links)
- CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma (Q33749646) (← links)
- Advances in the understanding of myeloma bone disease and tumour growth (Q33829022) (← links)
- Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis (Q34155848) (← links)
- Multiple myeloma macrophages: pivotal players in the tumor microenvironment. (Q34329152) (← links)
- Macrophages in multiple myeloma: emerging concepts and therapeutic implications (Q34329242) (← links)
- Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone (Q34420112) (← links)
- Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. (Q35475443) (← links)
- The proportion of CD16( )CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma (Q35648024) (← links)
- Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells (Q35754021) (← links)
- Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow (Q35834665) (← links)
- Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells (Q36092102) (← links)
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma (Q36213431) (← links)
- Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma. (Q36414426) (← links)
- Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities (Q36447553) (← links)
- Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation (Q36544094) (← links)
- Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells (Q36557393) (← links)
- MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages (Q36674532) (← links)
- Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo (Q36691554) (← links)
- Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma (Q36803165) (← links)
- PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma (Q36839558) (← links)
- The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. (Q36967153) (← links)
- Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression (Q36983876) (← links)
- Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy (Q37035522) (← links)
- Mechanisms of multiple myeloma bone disease (Q37056408) (← links)
- Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss (Q37144501) (← links)
- Targeting inflammasome/IL-1 pathways for cancer immunotherapy (Q37370733) (← links)
- Prognostic significance of absolute lymphocyte count/absolute monocyte count ratio at diagnosis in patients with multiple myeloma (Q37459108) (← links)
- Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway (Q37513938) (← links)
- Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma (Q37745835) (← links)
- The backbone of progress – preclinical studies and innovations with zoledronic acid (Q37847339) (← links)
- Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands. (Q37955105) (← links)
- Inflammation: what role in pediatric cancer? (Q37967667) (← links)
- MicroRNA-21 and multiple myeloma: small molecule and big function (Q38224963) (← links)
- Serotonin modulation of macrophage polarization: inflammation and beyond (Q38231265) (← links)
- Targeting the bone marrow microenvironment in multiple myeloma. (Q38289041) (← links)
- Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects (Q38336989) (← links)
- Role of tumor-associated macrophages in hematological malignancies. (Q38364405) (← links)
- The Hemopoietic Stem Cell Niche Versus the Microenvironment of the Multiple Myeloma-Tumor Initiating Cell (Q38569328) (← links)
- Myeloma and Bone Disease (Q38598342) (← links)
- A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies. (Q38634685) (← links)
- Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies (Q38708402) (← links)
- Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy (Q38781397) (← links)
- Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells (Q38810089) (← links)
- Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo. (Q38911659) (← links)
- Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche (Q38932298) (← links)